TABLE 1.
Antigen construct | Low-transmission season
|
High-transmission season
|
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
All samples
|
Positive responses only
|
All samples
|
Positive responses only
|
|||||||||
rs | P(rs) | n | rs | P(rs) | n | rs | P(rs) | n | rs | P(rs) | n | |
Wellcome 19 | 0.09 | 0.13 | 266 | 0.04 | 0.69 | 83 | 0.01 | 0.86 | 266 | −0.02 | 0.88 | 78 |
Wellcome EGF1 | 0.04 | 0.56 | 266 | 0.16 | 0.30 | 45 | 0.09 | 0.16 | 266 | −0.02 | 0.90 | 44 |
MAD20 EGF1 | 0.00 | 0.94 | 265 | 0.22 | 0.17 | 36 | −0.06 | 0.38 | 265 | 0.05 | 0.74 | 37 |
MAD20 EGF2 | 0.04 | 0.52 | 265 | −0.01 | 0.77 | 10 | −0.03 | 0.63 | 265 | −0.15 | 0.59 | 14 |
rs, Spearman rank correlation coefficient; P(rs), associated level of significance; N, number of samples tested.